Skip to main content
Translational Oncology logoLink to Translational Oncology
. 2025 Dec 17;64:102637. doi: 10.1016/j.tranon.2025.102637

Corrigendum to “Clinical significance and molecular mechanism of CDX2-CBX3 regulatory axis in lung adenocarcinoma progression” [Transl Oncol. 2025 Nov 10:63:102590]

Shicheng Liu a,b, Qingtao Zhao b, Dahu Ren b, Lingxin Kong b, Hongzhen Zhao b, Guochen Duan a,b,
PMCID: PMC12902240  PMID: 41539742

The authors regret < In Figure 8C, the same Transwell image was inadvertently duplicated for two experimental groups: the "control" group and the "OE-CDX2 + si-CBX3" group. This occurred due to an unintentional error during figure preparation. We have replaced it with a corrected version of Figure 8 with the appropriate images for each group. The correction does not affect the overall interpretation of the results or the conclusions of the study.>.

graphic file with name fx1.jpg

The authors would like to apologise for any inconvenience caused.


Articles from Translational Oncology are provided here courtesy of Neoplasia Press

RESOURCES